Based on these findings, we also postulate that the use of a minimal PLAD peptide will compete with this region and prevent CD95 self-association, altering the induction of CD95-mediated signaling pathways involved for instance in the severity of lupus [31, 32]. This evidence concerns the gene FAS and systemic lupus erythematosus.